Imugene gets ethics approval to start Phase 1 clinical trial of immunotherapy candidate for lung cancer in the US
Site activation and patient recruitment will proceed after FDA IND approval scheduled for the fourth quarter of 2020.
Company
Imugene Ltd
ASX:IMU
Imugene Ltd is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours. The company's unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Imugene is supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.
224 stories · page 8 of 12
Imugene receives third ethics approval to start phase-1 clinical trial of PD1-Vaxx cancer immunotherapy
The ethics approval represents the third independent review of PD1-Vaxx pre-clinical safety and efficacy data.
Imugene guidance from US FDA progresses development pathway for VAXinia product
The FDA provided feedback on the non-clinical development pathway and adaptive phase one clinical development plans for VAXinia, IMU’s lead oncolytic virotherapy for treatment of solid tumours.
Imugene managing director acquires 27 million shares via exercise of options
Last month, Imugene received Human Research Ethics Committee approval to begin a phase-I clinical trial of its cancer checkpoint immunotherapy candidate, PD1-Vaxx in Australia.
Imugene given all clear to start phase-1 clinical trial of new cancer immunotherapy PD-1 Vaxx in Australia
The ethics approval represents the second independent review of PD-1 Vaxx pre-clinical safety and efficacy.
Imugene receives ethics approval to start phase 1 clinical trial of new cancer immunotherapy PD1-Vaxx
Ethics approval is confirmation Imugene has completed all the necessary pre-clinical safety and efficacy testing of PD1-Vaxx required to commence human clinical trials.
Imugene research published in prestigious journal titled Frontiers in Immunology
The research has identified mimotope peptides that when incorporated into Imugene’s proprietary immunotherapeutic vaccine delivery platform generate antibodies.
Imugene secures speculative buy recommendation from Bell Potter
HER-Vaxx is Imugene’s lead cancer immunotherapy candidate and is currently treating patients in a phase 2 study in gastric cancer.
Imugene receives independent confirmation of HER-Vaxx safety
The Independent Data Monitoring Committee’s role is to review study data and conduct a formal independent review of key data such as deaths, adverse reactions and laboratory results.
Imugene to virtually present its immuno-oncology clinical plans at Cancer Research 2020
The first-in-human phase 1 study of Vaxinia is in patients with advanced or metastatic melanoma, non-small cell lung, TNBC, bladder, head and neck, gastric, colorectal and renal cell cancers.
Imugene well-placed to advance clinical trials this year
The company is developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours.
Imugene non-executive director Lesley Russell demonstrates faith in company with initial on-market purchase
The company is developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumors.
Imugene CEO Leslie Chong backs immuno-oncology strategy with further share purchase
The company's lead product is HER-Vaxx, a therapeutic cancer vaccine for the treatment of gastric cancer and breast cancer.
Imugene director Charles Walker makes another share purchase
The company is developing a range of treatments to activate the immune system of cancer patients.
Imugene director Charles Walker purchases more shares in the company
The company's lead product is HER-Vaxx, a therapeutic cancer vaccine for the treatment of gastric cancer and breast cancer.
Imugene CEO Leslie Chong demonstrates confidence in immuno-oncology strategy with on-market purchase
The clinical stage immuno-oncology company is developing a range of new treatments seeking to activate the immune system of cancer patients.
Imugene director shows faith in company strategy with on-market share purchase
The company's lead product is HER-Vaxx, a therapeutic cancer vaccine for the treatment of gastric cancer and breast cancer.
Imugene outlines its focus on developing immuno-oncology treatments in half-yearly report
The company's lead product is HER-Vaxx, a therapeutic cancer vaccine for the treatment of gastric cancer and breast cancer.
Imugene has CheckVacc preclinical data published in the Journal of American College of Surgeons
The company’s preclinical results present an effective treatment against Peritoneal carcinomatosis (PC) from pancreatic ductal adenocarcinoma (PDAC).
Imugene will trial PD1-Vaxx in patients with non-small cell lung cancer
Pre-clinical milestones have been met with GMP manufacturing, including final sterile fill and finish as well as processes completed by FDA inspected and qualified contract manufacturing organisations in the US.